Welcome to our dedicated page for Sanuwave Health SEC filings (Ticker: SNWV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sanuwave Health’s SEC documents can feel like you’re decoding clinical trial data and FDA nuances at the same time. Whether you’re tracing reimbursement risk in a 300-page annual report or scanning for new device revenue in a 10-Q, the stakes are high—especially when chronic wound-care adoption drives valuation. That’s why Stock Titan puts AI-powered summaries on every filing, turning dense medical terminology into plain-English takeaways investors can act on.
Searches like “Sanuwave Health quarterly earnings report 10-Q filing� or “Sanuwave Health 8-K material events explained� land you here because we map each question to the right form. Want insider confidence signals? Our platform streams Sanuwave Health Form 4 insider transactions real-time, flags option exercises, and keeps a historical log under “Sanuwave Health executive stock transactions Form 4.� Need the bigger picture? The Sanuwave Health annual report 10-K simplified section highlights device pipeline progress, R&D spend, and regulatory milestones. For governance detail, the “Sanuwave Health proxy statement executive compensation� tab breaks out PACE-based performance metrics without the legal clutter.
Every filing—from routine “Sanuwave Health insider trading Form 4 transactions� to surprise 8-K updates—is indexed seconds after EDGAR posts. Our AI spots shifts in wound-care reimbursement language, compares quarter-over-quarter revenue, and attaches concise context so you can stop scrolling and start deciding. If you’ve ever typed “understanding Sanuwave Health SEC documents with AI� or looked for “Sanuwave Health earnings report filing analysis,� you’ve just found the place investors rely on for clarity, speed, and total coverage.
ReTo Eco-Solutions, Inc. (RETO) filed a second amendment to its April 25 2025 Form 6-K to add the consent of its independent auditor, Wei, Wei & Co., LLP (Exhibit 23.1). The original 6-K and first amendment had disclosed and provided financials for ReTo’s acquisition of 5,100 ordinary shares of MeinMalzeBier Holdings Limited, completed the same day. No financial statements, pro-forma data, or transaction terms have been revised; the sole purpose of this filing is to supply the auditor’s consent so that the earlier financial information can be incorporated by reference into ReTo’s effective registration statements on Forms F-3 (File Nos. 333-267101 & 333-282314) and S-8 (File Nos. 333-270355 & 333-280119). The amendment is purely administrative and does not introduce new operational or financial developments.
The Vanguard Group filed Amendment No. 16 to Schedule 13G for Ross Stores (ROST), reporting ownership data as of 30 June 2025.
- Shares owned: 39,182,382
- Percent of outstanding: 11.97%
- Voting power: Sole � 0; Shared � 398,551
- Dispositive power: Sole � 37,629,201; Shared � 1,553,181
The filing is made under Rule 13d-1(b) as Vanguard acts as an investment adviser holding the shares in the ordinary course for its clients. The stake exceeds the 10% threshold, giving Vanguard a material yet passive position; the firm certifies no intent to influence control of the issuer. The statement is signed by Ashley Grim, Head of Global Fund Administration, on 29 July 2025.
Insider activity: Director Edward J. Rapp filed a Form 4 disclosing two equity grants made on 07/10/2025. He acquired 62,377 Restricted Stock Units (RSUs) that will vest on the earlier of 07/10/2026 or the eve of the 2026 annual meeting, and received an additional 1,601 RSUs in lieu of his Q2-2025 cash retainer for chairing the Audit Committee, which vested immediately. All shares were acquired at a cost of $0.
Post-transaction ownership: Rapp now holds 121,894 common shares directly (including 62,377 unvested RSUs) and 21,172 shares indirectly through a trust, bringing his total beneficial stake to 143,066 shares.
Key context:
- The grants are part of routine director compensation and were not open-market purchases.
- Vesting of the larger RSU block requires Rapp’s continued board service through 2026, signalling expected tenure stability.
- No derivative securities were reported, and no dispositions occurred.
Dare Bioscience, Inc. (DARE) filed a Form 4 disclosing the grant of 4,500 non-qualified stock options to independent director Jessica D. Grossman on 07/09/2025. The options carry an exercise price of $2.44 per share and expire on 07/09/2035.
Vesting terms: The award vests in full on the earlier of (i) the first anniversary of the grant date or (ii) immediately prior to the company’s first annual shareholder meeting following the grant. Full acceleration occurs upon a change in control, provided the director remains on the board.
Post-grant holdings: Following this transaction, Dr. Grossman beneficially owns 4,500 derivative securities (stock options) and no change was reported for common shares in Table I, indicating the grant is additive rather than a sale.
Governance context: Routine equity compensation for directors aligns incentives with shareholder interests but results in a modest potential dilution of approximately 0.01% of outstanding shares, assuming ~45 million shares outstanding (company total not provided in filing). No cash was exchanged and there is no immediate earnings impact.
PrimeEnergy Resources Corp. (PNRG) � Schedule 13D/A (Amendment 10)
Chairman, CEO and President Charles E. Drimal, Jr. discloses beneficial ownership of 1,374,070 common shares, equal to 58.3 % of the 1,660,500 shares outstanding on 14 May 2025. The stake comprises 520,644 directly-held shares, 697,500 fully-exercisable options at $1.00�$1.25, and 155,926 shares covered by six newly executed voting agreements dated 30 Jun 2025. No cash transactions occurred; the filing simply broadens Drimal’s voting power.
Drimal affirms no current intentions to pursue additional share purchases, divestitures, mergers, capital changes, or governance restructurings. The filing’s sole purpose is to record the incremental voting rights gained through the agreements; Drimal holds no dispositive power or economic interest in the 155,926 agreement shares.
The update gives management majority control, potentially streamlining strategic decision-making but also heightening governance-concentration risk for minority investors. Six voting-agreement exhibits are attached for reference.
- Total beneficial ownership: 1.37 M shares.
- Percent of class: 58.3 %.
- Options outstanding: 697,500 (possible dilution).
- Voting-agreement shares: 155,926 with no pecuniary interest.
On 30 June 2025, SANUWAVE Health, Inc. (ticker: SNWV) granted Director Jeffrey Blizard a fully-vested stock option covering 1,574 shares of common stock, as disclosed in a Form 4 filed on 2 July 2025. The option carries an exercise price of $32.86 and an expiration date of 30 June 2030. The transaction was coded �A,� indicating an issuer-awarded grant rather than an open-market purchase. No non-derivative transactions or additional derivative movements were reported.
Following this grant, Mr. Blizard directly owns 1,574 derivative securities and reported no other holdings in SNWV common stock. Because the options were already fully vested at issuance, they are immediately exercisable, potentially aligning the director’s incentives with shareholder value creation. However, the filing does not specify any accompanying cash outlay or further equity activity.
Form 4 filing overview � SANUWAVE Health, Inc. (SNWV)
Director Gregory M. Bazar reported one insider transaction dated 30 June 2025. The filing shows an award of 1,574 stock options (right to buy common stock) with an exercise price of $32.86 and an expiration date of 30 June 2030. The options were fully vested at the grant date, and Bazar now beneficially owns 1,574 derivative securities directly. No open-market purchases or sales of common shares were disclosed, and there were no changes to non-derivative share holdings.
The transaction appears to be routine director compensation and represents a limited potential dilution given the company’s outstanding share count. No other financial or operational information was provided in this filing.
Community Healthcare Trust Inc. (CHCT) filed a Form 4 disclosing that its Executive Vice President & Chief Financial Officer, William G. Monroe IV, had a single reportable transaction on 30 June 2025.
- Transaction code F indicates shares were withheld to satisfy tax obligations associated with equity compensation.
- 650 shares of common stock were disposed of at an average price of $16.77 per share.
- Following the transaction, Monroe directly owns 149,759 CHCT common shares.
- No derivative securities were acquired or disposed of, and no other transactions were reported.
The filing was signed on 2 July 2025 by attorney-in-fact Nathanael P. Kibler.
FAQ
What is the current stock price of Sanuwave Health (SNWV)?
What is the market cap of Sanuwave Health (SNWV)?
What core technology does Sanuwave Health utilize?
In which medical fields are Sanuwave Health's products applied?
How does Sanuwave Health's technology improve healing?
What is the business model of Sanuwave Health?
How does Sanuwave Health differentiate itself from competitors?
What is the significance of their end-to-end wound care portfolio?
How does the company ensure quality and regulatory compliance?
What makes Sanuwave Health relevant for investors?
